Page last updated: 2024-09-04

kw 2189 and Blood Diseases

kw 2189 has been researched along with Blood Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alberts, SR; Ames, MM; Erlichman, C; Goldberg, RM; Reid, JM; Richardson, RL; Sloan, JA1

Trials

1 trial(s) available for kw 2189 and Blood Diseases

ArticleYear
Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Duocarmycins; Female; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pyrrolidinones

1998